Adial Pharmaceuticals (ADIL) Projected to Post Quarterly Earnings on Wednesday

Adial Pharmaceuticals (NASDAQ:ADIL) is projected to post its Q3 2026 results on Wednesday, November 18th. Analysts expect Adial Pharmaceuticals to announce earnings of ($0.1750) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its quarterly earnings data on Friday, August 14th. The company reported ($11.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($10.22).

Adial Pharmaceuticals Price Performance

NASDAQ:ADIL opened at $4.88 on Wednesday. The firm has a market capitalization of $12.80 million, a price-to-earnings ratio of -0.33 and a beta of 1.50. Adial Pharmaceuticals has a 1 year low of $1.31 and a 1 year high of $9.30. The business has a 50 day simple moving average of $4.58 and a 200-day simple moving average of $3.24.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ADIL. Alliance Global Partners initiated coverage on Adial Pharmaceuticals in a research report on Monday, August 3rd. They set a “buy” rating and a $11.00 target price on the stock. Weiss Ratings upgraded Adial Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 28th. Finally, Wall Street Zen raised shares of Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, August 15th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.33.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for addiction and related disorders. The company’s primary product candidate is AD04, an investigational formulation of ondansetron, a serotonin 5-HT3 receptor antagonist, being developed as a pharmacogenetically targeted treatment for alcohol use disorder. AD04 is designed for people with alcohol use disorder who have specific genetic characteristics that may influence treatment response. Adial’s development approach combines pharmaceutical treatment with genetic testing to identify potentially responsive patient populations.